We compared ISB 1442 to clinically validated monospecific antibodies, anti-CD38 (daratumumab) and anti-CD47 (hu5F9, magrolimab) in several potency assays with tumor cell lines expressing varying levels of CD38 and CD47 (Supplementary Table 3). Here, CD47 is linked to neoplasm.